Shu-Chih Chen

Shu-Chih Chen is a declared insider of Atossa Therapeutics, Inc. (senior executive), with filings sourced from SEC (Form 4). Over a trading history stretching from 19 January 2016 to 12 May 2026, the count stands at 4 filings.

No open-market sale appears; the market trades are 3 purchases worth €21k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant.

In size, the median ticket on the buying side is €7,115. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -9.7%. Past outcomes like these are no guarantee of what comes next.

On 14 May 2026 came the latest disclosure, a share grant in Atossa Therapeutics, Inc. The most recent open-market purchase was published on 10 March 2016, 3,880 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.